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Resumo 
 
 
 
O desenvolvimento de biomateriais compósitos pode tirar partido de sinergias entre as proprieda-
des benéficas de dois ou mais materiais numa nova e sofisticada matriz, uma vez que poucos 
biomateriais possuem todas as características necessárias para apresentarem um desempenho 
ideal. O osso é um exemplo perfeito de um material compósito criado pela natureza. 
O principal objetivo deste estudo foi o de produzir um biomaterial compósito para a regeneração 
do tecido ósseo. O material desenvolvido é composto por uma hidroxiapatite reforçada com biovi-
dro (Bonelike), que já demonstrou alta bioactividade e boa osteointegração, e um hidrogel biode-
gradável, feito a partir de dextrino oxidado (hidrogel oDex). O hidrogel irá funcionar como veículo 
injectável para os grânulos do Bonelike. 
Para melhorar as características do injectável, o sistema foi estudado e modificado para actuar 
como um transportador de fármaco, nomeadamente de simvastatina, que tem reportado a capa-
cidade de promover actividade osteoblástica e inibir a actividade osteoclástica. Primeiramente, o 
Bonelike foi testado como um transportador para a simvastatina e apresentou uma libertação lenta 
e gradual do fármaco. Em seguida, tirando partido das capacidades da nanotecnologia no campo 
da administração de fármacos, nanopartículas de dextrino foram utilizadas para melhorar a solu-
bilização da simvastatina e controlar o seu perfil de libertação. As nanopartículas carregadas com 
simvastatina, sob as condições testadas, formam uma solução estável que liberta o fármaco em 24 
horas, e revelaram de um modo geral boa biocompatibilidade. 
O novo biomaterial injetável compósito para aplicações em regeneração óssea apresenta boas ca-
racterísticas de injectabilidade e propriedades promissoras como um veículo injectável para a 
simvastatina. 
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Abstract 
 
 
 
Given that few biomaterials possess all the required characteristics to perform ideally, the devel-
opment of composite biomaterials can synergize the beneficial properties of two or more materials 
into an improved new matrix. Bone is a perfect example of a composite material designed by 
nature.  
The primary purpose of this study was to produce a composite biomaterial for bone tissue regen-
eration. The developed material is composed by a glass reinforced hydroxyapatite (Bonelike), that 
have already demonstrated high bioactivity plus good osteointegration, and a biodegradable hy-
drogel, made from oxidized dextrin (oDex hydrogel). The oDex hydrogel will perform as an inject-
able carrier of the Bonelike granules.  
To enhance the characteristics of the injectable, the system was studied and modified to act as a 
drug carrier of simvastatin, a drug that has been reported to promote osteoblastic activity and 
inhibit osteoclastic activity. At first, Bonelike was tested as a carrier for simvastatin and showed 
a slow and gradual release of the drug over 2 weeks. Then, taking advantage of nanotechnology in 
the drug delivery field, dextrin nanoparticles were used for improving simvastatin solubilisation 
and controlling its release profile. The simvastatin loaded nanoparticles, under the conditions 
tested, form a stable solution that release its content in a 24 hours time frame and revealed an 
overall good biocompatibility.  
The new injectable composite biomaterial for bone regeneration present good extrusion charac-
teristics and promising properties as an injectable carrier of simvastatin.  
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Chapter 1  
Motivation and main goals 
 
 
 
Biomaterials degree of sophistication has increased significantly; the actual trend is towards 
biomaterials that are capable of perform active roles, in which they can assist and promote 
tissues regeneration. 
Selecting an appropriate material can lead to an improvement on the quality of the newly 
formed tissue. The major challenge for the field of tissue engineering is the identification or 
development of biomaterials capable of promoting the desired outcome. Given that few bio-
materials possess all the required characteristics to perform ideally, the development of hybrid 
or composite biomaterials can synergize the beneficial properties of two or more materials into 
an improved new matrix.  
In this work, the development of a composite biomaterial for bone tissue regeneration was 
attempted. It is composed by a glass reinforced hydroxyapatite (Bonelike), that has a compo-
sition very similar to the bone mineral phase and have already demonstrated high bioactivity 
plus good osteointegration, and a biodegradable hydrogel, made from dextrin (oDex hydrogel), 
a glucose polymer with low molecular weight. The oDex hydrogel will perform as an injectable 
carrier of the Bonelike granules.  
To enhance the characteristics of the injectable formulation, different strategies were selected 
and tested. The capacity of the system to act as a drug carrier of simvastatin (a cholesterol-
lowering drug that recently has been reported to promote osteoblastic activity and inhibit os-
teoclastic activity) was tested. It is expected that simvastatin will bring osteogenic properties 
to the bone graft material; however, the current level of evidence regarding regenerative ap-
plications of simvastatin has not been established in a systematic way, owing to this line of 
research still being very recent.  
Self-assembled nanoparticles are promising nanotecnhological tools with potencial in the drug 
delivery field. In this work, dextrin nanoparticles and Bonelike were selected as carriers for the 
simvastatin and a release study was performed. The cytotoxicity of the simvastatin loaded na-
noparticles was also evaluated.  
The injectability of the whole system was also assessed, with the view to its application in 
clinical environment. 
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Chapter 2 
State of the art 
 
 
 
2.1 Bone 
2.1.1 Structure 
Bone tissue is the major structural and supportive connective tissue of the body. It is a living, 
highly vascularized, dynamic, mineralized connective tissue that forms the skeleton of the most 
vertebrates [1], [2]. 
Bone presents a unique structure and mechanical properties: it is one of the most rigid and 
resistant tissue of the human body and have relatively light structure, capable of supporting 
considerable forces and able to remodel and repair itself. Bone is a dense multi-phase material 
or composite made up of cells embedded in a matrix composed of both organic and inorganic 
elements [1], [3], [4]. 
However, its structure and proportion of its components differ widely with age and site, result-
ing in different classifications of bone that exhibit various mechanical and functional charac-
teristics [1].  
The skeleton is designed to protect the vital organs of the body and provide the frame for 
locomotion of the musculoskeletal system. Furthermore, bone is a reservoir for many essential 
minerals, such as calcium and phosphate, and plays an important role in the regulation of the 
ion concentrations in extracellular fluid [5].  
Bone marrow contains mesenchymal stem cells (MSCs), which are multipotent cells capable of 
differentiation into bone, cartilage, tendon, muscle, skin and fat tissue. In this cavity, there 
are also different kinds of hematopoietic cells that produce the red and white blood cells, that 
have the function of gas transportation and immune resistance, respectively [5], [6] .  
The adult human skeleton is composed of 20% trabecular bone and 80% cortical bone (figure 
2.1) [7]. In the body, different bones show different percentages of cortical and trabecular 
bone [8].  
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Figure 2.1 - Cortical bone and trabecular bone [7]. 
 
Cortical bone is also called compact bone or haversian bone and it is typically found in the 
shafts of long bone and the vertebral endplates [9]. Cortical bone has only 10% of porosity, whit 
a small number of cells and blood vessels. The structural unit of cortical bone is the cylindric 
shaped osteon, which is composed of concentric layers of bone called lamella [5], [10]. Blood 
vessels are present along the Haversian canals located at the center of each osteon. The nutri-
ent diffusion is further allowed by microscale canals within the bone. Osteons are aligned in 
the longitudinal direction of bone and therefore, cortical bone is anisotropic [5].  
Trabecular bone is also called cancellous bone and is primarily found in the vertebral bodies, 
pelvis, and distal ends of long bones [9]. Trabecular bone, which may has as much as 50 – 90 % 
pores, is an interconnected network of small bone trusses (trabecula) aligned in the direction 
of loading stress. The porous of cancellous bone contains vessels and bone marrow, which pro-
vides lower mechanical support compared to cortical bone [5], [9].  
 
2.1.2 Extracellular matrix and bone cells 
Bone tissue is essentially constituted of an extracellular matrix and three main cell types. The 
extracellular matrix is a composite of inorganic (65%) and organic (35%) phases. Calcium-con-
taining minerals are the components of the inorganic part. The organic part of the extracellular 
matrix is composed of collagen type I and numerous noncollagenous proteins, like bone sialo-
protein, osteocalcin and osteopontin [11]. This organic matrix is calcified by the deposition of 
crystals of the mineral phase, which is a highly substituted hydroxyapatite [12]–[14]. 
 
Three types of differentiated cells inhabit the organic-inorganic composite structure of bone. 
These cells are osteoblasts, osteoclasts and osteocytes [5], [15], [16]. 
The osteoblasts are fully differentiated cells responsible for the production of the extracellular 
bone matrix and its mineralization and they also manufacture hormones, such as prostaglan-
dins, to act on bone itself. They produce alkaline phosphatase, an enzyme that has a role in 
bone mineralization.  Osteoblasts originates from less differentiated precursor cells known as 
osteoprogenitor or MSCs [16]–[18].   
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Osteocytes are the most abundant cell type in bone. They are responsible for bone matrix 
maintenance by secreting enzymes and maintaining its mineral content. The osteocytes derive 
from osteoblasts and they are not on the bone surface but regularly entrapped throughout the 
extracellular matrix [16], [17].  
Osteoclasts are giant multinucleated cells responsible for bone resorption. Unlike osteoblastic 
cells, osteoclasts are derived from hematopoietic cell lines of macrophage/monocyte linage. 
Osteoclasts differentiation occurs within the bone microenvironment, where interaction be-
tween monocyte precursors and osteoblasts enables the cells to differentiate into osteoclasts 
[16], [17], [19].  
 
2.1.3 Bone remodeling and repair 
Bone is a living organ that undergoes remodelling throughout life. Bone remodeling is an active 
and dynamic process that relies on the correct balance between bone resorption by osteoclasts 
and bone deposition by osteoblasts (figure 2.2) [20], [21].  Bone remodeling involves the re-
moval of mineralized bone by osteoclasts followed by the formation of bone matrix through the 
osteoblasts that subsequently become mineralized. The remodeling cycle consists of three con-
secutive phases: resorption, during which osteoclasts digest old bone; reversal, when mononu-
clear cells appear on the bone surface; and formation, when osteoblasts lay down new bone 
until the resorbed bone is completely replaced [19]. 
 
 
Figure 2.2 - Bone remodeling process [21]. 
 
Moreover, these functions must be tightly coupled not only quantitatively, but also in time and 
space. When the coupling is lost, the correct bone mass could be compromised, leading to 
several skeletal pathologies [20].  
The process of fracture healing can be considered a form of tissue regeneration. However, 
despite the regenerative capacity of skeletal tissue, this biological process sometimes fails and 
fractures may heal in unfavourable anatomical positions, show a delay in healing or even de-
velop pseudoarthrosis or non-unions [22], [23]. 
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Healing occurs in three distinct but overlapping stages: the early inflammatory stage; the repair 
stage; and the late remodeling stage (figure 2.3) [23], [24]. 
In the inflammatory stage, a hematoma develops within the fracture site during the first few 
hours and days. Inflammatory cells (macrophages, monocytes, lymphocytes, and polymorpho-
nuclear cells) and fibroblasts infiltrate the bone under prostaglandin mediation. This results in 
the formation of granulation tissue, ingrowth of vascular tissue, and migration of mesenchymal 
cells. The primary nutrient and oxygen supply of this early process is provided by the exposed 
cancellous bone and muscle [25], [26].  
During the repair stage, fibroblasts begin to lay down a stroma that helps support vascular 
ingrowth. With the progress of the vascular ingrowth, a collagen matrix is laid down while 
osteoid is secreted and subsequently mineralized, which leads to the formation of a soft callus 
around the repair site. This callus is very weak, in terms of resistance to movement, during the 
first 4 to 6 weeks of the healing process and usually requires adequate protection in the form 
of bracing or internal fixation, being these events related to the orthopaedic area.  Eventually, 
the callus ossifies, forming a bridge of woven bone between the fracture fragments. Otherwise, 
if proper immobilization is not applied, ossification of the callus may not occur, and an unstable 
fibrous union may develop instead [23], [25]. Fracture healing is completed during the remod-
eling stage in which the healing bone is restored to its original shape, structure, and mechanical 
strength [19], [25].  
 
 
2.2 Bone grafts 
 
2.2.1 Introduction 
The field of biomaterials incorporates a broad spectrum of ideas, sciences and technologies, 
and it is in constant evolution. The applications of materials to problems in biology and medi-
cine requires follow the medical needs and the technological advance and research, always 
considering the ethical concerns and implications [27].   
Advances in engineering - for example nanotechnology - are greatly increasing the sophistica-
tion with which biomaterials are designed and have allowed fabrication of materials with in-
creasingly complex functions [28].  
Figure 2.3 - Process of fracture healing: (a) inflammation, (b) soft callus, (c) hard callus and (d) remod-
elling [24]. 
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Biomaterials are widely used to replace and/or restore the function of traumatized or degen-
erated tissues or organs, and thus improve the quality of life of the patients. The first and 
foremost requirement for the choice of the biomaterial is its acceptability by the human body. 
The most common classes of materials used as biomedical materials are metals, polymers, ce-
ramics, and composite. These four classes are used singly and in combination to form most of 
the implantation devices available today [29].  
 
 
2.2.2 Bone grafts 
Autograft bone is the bone of a patient for use in grafting procedures in their own body. Bone 
is taken from one part of the body and grafted onto another to replace damaged tissues (figure 
2.4). This procedure present a high probability of successful bone fusion, non-rejection and 
absence of transition of diseases [30]. Despite having osteogenic, osteoinductive and osteocon-
ductive properties, autograft procedure involves a second surgery to harvest the bone graft and 
could result in additional chronic pain at the site where the bone was harvested [31]. Besides 
that, the quantities of autograft bone are limited and the mortality of the tissue related with 
the harvesting is around 10% [30].  
An allograft is a graft between genetically non-identical members of the same specie. An allo-
graft may be obtained from living donors who are having bone removed during surgery or ca-
daveric ones. In these cases, there are no limitations with the volume of available tissue, and 
it is not necessary a second surgery in the patient [32]. It is possible to obtain a different variety 
of physical forms, like powder, gel, fibers, pastes, etc [33]. The major disadvantage of this 
graft is the transmission of diseases. Due to processing and sterilization, the graft loses the 
osteogenic capacity and presents the possibility of rejection [33]–[35]. 
Xenograft bone substitute has its origin from a species other than human, such as bovine bone 
and porcine bone and, more recently, coral [36]. However it is necessary several treatments 
such antigenic, demineralization and deproteinization, resulting in a loss of osteoinductive ca-
pacity [37]. The principal advantage is the large amount of available material; however, the 
risk of viral and bacterial diseases still occurs [38].  
Figure 2.4 - Various types of bone graft sources. 
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Although autograft is still perceived as the gold-standard material in bone grafting, the wide 
array of alternatives available in the market has resulted in a gradual shift towards increased 
adoption of bone grafts and substitutes, especially in the US and European market. The global 
bone grafts and substitutes market value will increase steadily over the coming years, rising 
from almost $2.1 billion in 2013 to approximately $2.7 billion by 2020, at a Compound Annual 
Growth Rate of 3.8% [39].  
 
 
2.2.3 Synthetic materials 
 
2.2.3.1 Calcium phosphate-based materials 
Due to their abundance in nature and presence in living organisms, calcium apatites and other 
calcium orthophosphates remain the chemical compounds of a special interest in many fields 
of science, including geology, chemistry, biology and medicine [40]–[42]. Synthetic materials, 
such as calcium phosphate ceramics (e.g. hydroxyapatite (Ca10(PO4)6(OH)2, HAp), tricalcium 
phosphate (Ca3(PO4)2, TCP), dicalcium phosphate (Ca2P2O7, DCP) and tetracalcium phosphate 
(Ca4P2O9, TeCP), etc.) are graft materials used in the bone tissue regenerative process [38], 
[43]–[45]. 
Successful bone grafting has to follow four basic criteria: osteoinduction, osteoconduction, os-
teogenesis, and stability [30]. Osteoinduction refers to the stimulation of osteoprogenitor cells 
to differentiate into osteoblasts that then begin new bone formation. Osteoconduction is the 
process which provides a structural framework and environment that supports the migration, 
attachment and growth of osteoblasts and osteoprogenitor cells into the graft. Osteogenesis 
refers to cellular process of new bone formation by osteoblasts following osteoinduction [46]. 
Finally, stability, or movement resistance ability at the union site, is crucial to avoid delayed 
neovascularisation, which could result in an inadequate growth of the newly formed bone over 
the bone graft leading to pseudoarthrosis [30], [38], [43], [47]. 
Calcium phosphate-based materials are of great interest for use as bone synthetic graft mate-
rials due to their chemical and biological properties, similar to human bone [43], [47]. These 
graft materials do not possess the risk of disease transmission and eliminate the need for an 
additional surgical procedure for transplantation, reducing patient pain and recovery time [38], 
[47]. In regenerative medicine, bone graft to restore skeletal integrity, give mechanical support 
and enhance bone healing is used in several orthopaedic, dental and maxillofacial proce-
dures[48]–[54]. 
 
2.2.3.2 Bioactive glasses and glass-ceramics 
Bioactive glasses are amorphous materials and glasses ceramics are polycrystalline materials 
composed of one or more glassy and crystalline phases. For the preparation of glass-ceramic 
materials there are three main techniques used: casting and controlled crystallization; sintering 
and crystallization of glass powder; and sol-gel technique [55]–[57].  
Almost all of the bioactive glasses and glass-ceramics currently used contain large amounts of 
silica (SiO2). Specific additives may be incorporated into the base glass composition to induce 
the nucleation and growth of particular crystal phases, within the residual vitreous matrix, with 
specific physicochemical properties in order to obtain glass-ceramics. The characteristics of 
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the final constituent phases and microstructure of the glass-ceramic establish its properties 
and main applications. The most well-known glass-based materials are Bioglass®, Ceravital® 
and Cerabone® A/W [58]–[60]. Several clinical applications of bioactive glasses and glass ce-
ramics are reported in the literature [61]–[66].  
All materials elicit a response from the host when implanted in living tissues. Generally, both 
tissue and material undergo physical and/or chemical modifications. Based on these modifica-
tions, ceramics can be classified as nearly inert ceramics, surface reactive ceramics (bioactive) 
and bioresorbable ceramics [67]–[69]. The nearly inert ceramics such as alumina and carbons 
are chemically stable and elicit minimal response within the surrounding tissue, maintaining its 
characteristics throughout the entire period of implantation in the organism [27], [70], [71].  
The surface reactive ceramics are midway between nearly inert and resorbable in behaviour. 
This kind of ceramic elicits a biological response to facilitate a direct chemical bond between 
the material surface and the surrounding tissues. The glass-based materials are considered sur-
face reactive ceramics and some examples included in this group are bioactive glasses (Bio-
glass®) and glass-ceramics (Ceravital®, Cerabone A/W)[27], [58], [70], [72]. When implanted, 
the materials undergo dissolution and release ions into the surrounding environment with con-
sequent local pH changes. The composition of the materials controls their surface reactivity. 
These kinds of materials do not become encapsulated when implanted, but closely adhere to 
the surrounding living bone tissues. The glass, glass-ceramics and calcium phosphates that show 
the ability to bond to bone after implantation became known as bioactive ceramics [73], [74]. 
Bioresorbable ceramics are designed to degrade progressively with time and be replaced with 
natural host tissue, without toxicity and rejection. Bioresorbable materials may show some 
complications in the clinical use, such as maintenance of strength and stability, and matching 
resorption rates to the repair rates of body tissues. This point is very important, since some 
materials display precocious resorption or delayed resorption. Since a great concentration of 
ions or/and particles of a bioresorbable material is released, it is important that it consists only 
of metabolically tolerable substances, which restricts the material’s compositional design and 
therefore the mechanical behaviour and eventually its final applications [27], [68], [75], [76]. 
 
2.2.3.3 Glass reinforced apatite 
A synthetic hydroxyapatite sintered in the presence of CaO-P2O5 based glasses, forms a material 
patented as Bonelike®, that was designed to improve the mechanical properties of calcium 
phosphate ceramics and mimic the inorganic composition of bone tissue [49], [52], [77], [78]. 
Its composition has the advantage of mimicking the mineral composition of natural bone. In 
fact, the addition of CaO-P2O5 based glass into the HAp structure leads to the formation of 
secondary phases, α- and β-TCP. Their percentage is dependent upon the sintering treatment, 
content and the composition of the glass added. Due to the presence of α- and β-TCP in the 
HAp matrix of Bonelike® the mechanical properties of the material are improved. Furthermore, 
this biodegradable and bioresorbable phases allow a local enrichment in calcium, phosphorous 
and several ionic species, such as magnesium, sodium and fluoride, that in physiological condi-
tions uphold a positive effect in the biomaterial’s behaviour since they promote osteointegra-
tion and enhance bone regeneration [79], [80]. 
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Clinical applications of Bonelike® in maxillofacial surgery indicate perfect bone bonding be-
tween new bone formed and Bonelike granules, along with partial surface biodegradation. This 
quick and effective osteoconductive response from Bonelike reduce the time needed to recon-
struct the bone defected area of patients [50], [81] . 
The controlled biodegradation of Bonelike® strongly enhances new bone formation and stimu-
lates the revascularization of the bone tissue. A clinical report were Bonelike® was implanted 
in eleven patients, to repairing surgical cystic bone defects, showed that  after 48 weeks of 
implantation all the patients showed high bone regeneration and none of the patients presented 
any symptoms of rejection or infection [81]. 
 
2.2.4 Injectable bone graft substitutes  
Injectable bone substitutes that are self-setting in situ can bring substantial benefits in some 
clinical situations, such as augmentation of osteoporotic fractures, treatment of maxillofacial 
defects and deformities. In fact, the orthopaedic community is still within the learning curve 
in many aspects of many of these products since they were introduced to the market not long 
ago [82], [83].  
 
Most injectable bone substitutes consist of a powder and a liquid or gel that are mixed imme-
diately before use [82], [83]. The ability of the surgeon to properly mix and inject the material 
within the prescribed time is crucial. In addition, the force needed to extrude the material 
should be taken into consideration.  
In table 2.1, a research was made to quantify some of the injectable bone graft substitutes 
that were commercially available in 2014. The Food and Drug Administration (FDA) approved 
all products presented in the table [83], [84].  
 
 
Table 2.1 - Injectable bone grafts commercially available 
 
Company 
Commercially available 
product 
Composition 
AlloSource AlloFuse Heat sensitive copolymer with DBM 
Biomet Osteobiologics InterGro DBM in a lecithin carrier 
Exactech 
Optecure DBM suspended in a hydrogel carrier 
Optefil DBM suspended in a gelatin carrier 
Integra Orthobiologics 
Accell Evo 3 
DBM, Accel Bone Matrix and Reverse 
Phase Medium 
DynaGraft II DBM and Reverse Phase Medium 
OrthoBlast II 
DBM, cancellous bone and Reverse 
Phase Medium 
Life Net Health Optium DBM DBM combined with glycerol carrier 
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BioHorizons 
Osteofil DBM DBM in porcine gelatin 
Progenix Putty 
DBM in Type-1 bovine collagen and 
sodium alginate 
MTF/Synthes DBX DBM in sodium hyaluronate carrier 
Osteotech GRAFTON gel DBM in a syringe 
Smith & Nephew VIAGRAF DBM combined with glycerol 
Wright Medical Tech-
nology 
PRO-DENSE injectable 
Regenerative Graft 
75% calcium sulphate and 25% cal-
cium phosphate 
 
 
The polymers used as carriers must have rheological, mechanical and biological properties ap-
propriate to its applications and the site of the implant [83], [85], [86]. Possible toxicity of 
degradation products and their elimination routes also need to be considered [85]. These in-
jectable systems should allow minimally invasive implantation, fill a desired shape, and easy 
incorporation of various therapeutic agents [85]. 
In fact, one of the most attractive features of injectable bone substitutes, besides providing 
mechanical support, is their potential use for controlled release of therapeutic or bioactive 
agents [87].   
 
 
 
2.3 Hydrogels 
 
2.3.1 Introduction 
Hydrogels are water-swollen polymeric materials, with a stable three-dimensional structure 
that provide scaffolds for tissue engineering, wound dressings, and drug delivery systems, 
among other application[88]–[90].  
Depending on their method of preparation, ionic charge, or physical structure features, hydro-
gels maybe classified in several categories. Based on the method of preparation, they may be 
homopolymer hydrogels, copolymer hydrogels, multipolymer hydrogels, or interpenetrating 
polymeric hydrogels[91], [92].  
Hydrogels remain as appealing candidates to tissue engineering scaffolds, due to the controlla-
ble and reproducible polymer properties and to the large water uptake, promoting excellent 
biocompatibility due to low protein adsorption [27]. In addition, hydrogels present mechanical 
properties and hydrophilicity that resembles those of the extracellular matrix (ECM) of native 
tissue, tunable viscoelasticity, and high permeability for oxygen and essential nutrients[93]–
[97]. Despite from the favorable physico-chemical and mechanical properties, the most im-
portant requirement for a hydrogel to be used in medical applications is its biocompatibility 
and the non-cytoxicity of its degradation products [98], [99]. 
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Injectable hydrogels can be maintained in the liquid state before injection and harden after 
transplantation in vivo. The hydrogel allows the filling of irregular defects, decreases the risk 
of implant migration and minimizes surgical defect to the size of a needle. In addition, the 
hydrogel can be incorporated with therapeutic factors and cells[100]. Hydrogels can also be 
stimuli-sensitive and respond to temperature, pH, electric field, glucose and antigens, among 
others. This way the hydrogel can have a controlled drug release due to volume changes [101]. 
Hydrogels present some limitations regarding drug delivery such as the high water content and 
large pore sizes that frequently result in relatively rapid release. Recently, composite systems 
where micro or nano hydrogels are incorporated in a bulk hydrogel matrix emerge as a platform 
for drug delivery [102]–[104]. The micro or nano hydrogel particles can act as a drug reservoir 
from which release can be triggered by a suitable stimulus or simply released in a diffusion-
controlled manner [104]. The major advantage relies on the improvement of the kinetic release 
profile of the drug, as the nanogel phase provides an additional diffusion barrier moderating or 
eliminating the initial burst release typically observed in hydrogel or nanogel drug delivery 
systems [105].  
Within the large range of materials used in the development of hydrogels, polysaccharide-based 
materials have been referred to as promising materials, presenting appealing properties for 
biomedical applications[27], [92], [106], [107]. 
Among the numerous macromolecules that can be used for hydrogel formation, polysaccharides 
are advantageous compared to synthetic polymers since they are coming from renewable 
sources. Polysaccharides have also frequently economic advantages over synthetic materials 
and they are usually non-toxic, biocompatible and show a number of convenient physico-chem-
ical properties such as viscosity, hydrophilicity and reactive groups [108]. The major disad-
vantages of natural polymers, when compared with synthetic ones, are the difficulty in con-
trolling their physico-chemical properties, such as molecular weight, strength, degradation 
time and mechanical properties. However, there are several strategies to overcome these lim-
itations, like the combination with other natural (e.g., collagen/glycosaminoglycans) or syn-
thetic polymers (e.g., collagen/PLGA). This combinations, may improve the biocompatibility of 
the ensuing scaffolds, by reducing inflammatory response in vivo and improving initial cell at-
tachment and differentiation on the material [109]–[112]. Polysaccharides, such as starch, cel-
lulose, chitin/chitosan, alginate, carrageenan, gellan, guar gum, hyaluronic acid, pullulan, 
among others, have been used in the formulation of several hydrogels [113]–[121]. 
 
 
2.3.2 Dextrin hydrogel 
Among starch-based materials, those based on dextrin are widely used in a variety of applica-
tions, since adhesives used in food to textile industries [122], peritoneal dialysis solution [123] 
and the cosmetic industry [124].  
Dextrins are a group of low-molecular-weight carbohydrates produced by partial hydrolysis of 
starch, which can be accomplished by the use of acid, enzymes, or a combination of both. 
Dextrin is a glucose-containing saccharide polymer linked by α-1,4 D-glucose units, containing 
few (< 5%) α-1,6 links, having the same general formula as starch, but smaller and less complex 
(figure 2.5) [107], [123]. 
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Figure 2.5 - Structure of Dextrin [125]. 
 
Due to its proven clinical tolerability [126] and its efficient absorption due to degradation by 
amylases [105], [127], [128], dextrin appears as a polymer that might be ideal for development 
as a drug carrier [123]. 
Dextrin hydrogels can be obtained by crosslinking following oxidation. The oxidized dextrin is 
characterized by their oxidation degree, which consists on the quantification of aldehyde 
groups. The oxidation reaction is characterized by the specific cleavage of the C2-C3 linkage 
of glucopyranoside rings, yielding two aldehyde groups per glucose unit (figure 2.6).  
 
 
Figure 2.6 - Periodate Oxidation of Dextrin, Yielding Two Aldehyde Groups at Positions C2 and C3 of a 
D-Glucose Unit [105]. 
 
The degree of oxidation (DO) can be easily controlled by the relative quantity of sodium perio-
date used, yielding free aldehyde reactive groups to create covalent linkages with reticulating 
molecules, cellular adhesion binding peptides or specific drugs for controlled delivery systems 
[105].  
In recent works, dextrin-hydroxyapatite complex was used as a bone filling material, with good 
performance [129]. Dextrin hydrogels, namely, dextrin-vinyl acrylate (Dex-VA) and dextrinhy-
droxyethylmethacrylate (Dex-HEMA) was shown their noncytotoxicity as well as their appealing 
diffusivity and degradability profiles for targeted delivery therapeutics [107], [130]. 
The concentration of dextrin that guarantees the ideal texture is between 30% and 40%, giving 
rise to an injectable hydrogel; above 40%, the solution is extremely viscous and very difficult 
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to homogenize. A polymer concentration below 25% will originate a viscous fluid instead of a 
hydrogel. The crosslinking times of the hydrogel is between 5-30 minutes. If used in maxillofa-
cial surgery applications, as an adjuvant to osteogenic granular compounds, this time would 
allow an unhurried handling and implantation [107], [125].  
 
 
2.3.3 Dextrin nanogel 
Polymeric nanogels, also referred to as hydrogel nanoparticles, macromolecular micelles or 
polymeric nanoparticles, are emerging as promising drug carriers for therapeutic applications 
[131].  
The study of nanogels has intensified during the past two decades due to enormous potential 
applications in the development and implementation of new environmentally responsive mate-
rials, biomimetics, biosensors, artificial muscles and drug delivery systems [132]. Solid nano-
particles made from biodegradable polymers for long-term delivery of drugs can potentially 
provide benefits such as increased therapeutic effect, prolonged bioactivity, controlled release 
rate, and finally decreased administration frequency, thereby increasing patient compliance 
[133].  
Among the available nanosystems, self-assembled polymeric nanogels, like dextrin nanogel, are 
particularly attractive, since they are easy to produce, affordable and may effectively incor-
porate a variety of drugs [132].  
Gonçalves et al. developed and characterized self-assembled nanoparticles of dextrin with 
great potential for biomedical applications [131], [134]–[138]. In vitro studies with bone mar-
row-derived macrophage revealed that the nanoparticles are non-cytotoxic and do not elicit a 
reactive response when in contact with macrophages [136]. Dextrin nanoparticles served as an 
effective nanocarrier for the formulation of lipophilic curcumin by increasing its water solubil-
ity, improving its stability, and controlling its release profile, without compromising the cyto-
toxicity in HeLa cell line [138].  
 
 
2.4 Simvastatin in bone regeneration  
Currently, researchers are searching for bone graft materials with the advantages of autologous 
bone grafts (osteogenesis, osteoinduction and osteoconduction), but without their disad-
vantages (donor site morbidity, difficulty of storage and maintenance, unlimited availability, 
etc.) [139].  
In 1980, Urist reported the identification in the rat organic bone matrix of an insoluble protein 
of low molecular weight called Bone Morphogenetic Protein, BMP [140]. BMPs are multi-func-
tional growth factors that belong to the transforming growth factor beta (TGFbeta) superfamily 
[141].  BMP signaling plays critical roles in heart, neural and cartilage development and play an 
important role in postnatal bone formation. Preclinical and clinical studies have shown that 
BMP-2 can be utilized in various therapeutic interventions such as bone defects, non-union 
fractures, spinal fusion, osteoporosis and root canal surgery [141]. BMP-2 and BMP-7 are oste-
oinductive BMPs: they have been demonstrated to potently induce osteoblast differentiation in 
a variety of cell types [141], [142]. However, the use of BMPs entails some problems such as 
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their short life, storage and handling difficulties, inefficiency in the recognition of target cells, 
and high cost, which has hindered its popularization in procedures for regeneration of bone 
tissue [139], [143]. 
As alternatives of BMPs, some authors have suggested the topical use of drug compounds aimed 
at upregulating intrinsic bone growth factors. For example, some widely known pharmacologic 
compounds (such as bisphosphonates or statins) have recently been shown to upregulate bone 
growth through distinct and complex biochemical pathways [144]–[147]. 
In 1999, was first reported, by Mundy et al., that lovastatin and simvastatin stimulate bone 
regeneration when injected subcutaneously in mouse calvaria [148]. Statin is a specific inhibitor 
of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase, rate-limiting enzyme of the 
cholesterol synthesis pathway [149]. Simvastatin (figure 2.7) [150], a chemical modification of 
lovastatin, is an inactive lactone drug that, after oral administration, is converted to its active 
dihydroxy open acid form by the intracellular enzyme cytochorome P450 (3A4 isozyme) in the 
liver [149]. Simvastatin is not well absorbed, and less than 5% of an oral dose reaches the 
systemic circulation. Concentrations of statins in bone marrow have not been well established 
yet, but osteoblasts and osteoclasts may be exposed to very low concentrations of statin with 
existing oral regimens [151].  
 
 
Figure 2.7 - Structure of simvastatin [150]. 
 
Simvastatin is suggested to support bone morphogenetic protein (BMP)-induced osteoblast dif-
ferentiation through antagonizing TNF-α-to-Ras/Rho/mitogen activated protein kinase and aug-
menting BMP-Smad signalling [152]. Simvastatin increases alkaline phosphatase activity and 
mineralization, as well as increases the expression of bone sialoprotein, osteocalcin and type I 
collagen, and it is shown to have anti-inflammatory effect by decreasing the production of 
interleukin-6 and interleukin-8 [153].  
Simvastatin has been reported to promote osteoblastic activity and inhibit osteoclastic activity. 
There have been many studies demonstrating the bone promoting effect of local application 
with different carriers in various animal models [154]–[156].  
The use of topical simvastatin for bone regeneration can be seen as a relatively recent research 
line, since most studies have been carried out in the last 5 years [139]. 
The successful use of simvastatin to promote bone formation in vivo depends on the local con-
centration [154]. Therefore, an appropriate carrier would bring several advantages, including 
localization and retention of the molecule to the site of application thus reducing the loading 
dose and providing a matrix for mesenchymal cell infiltration and a substrate for cell growth 
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and differentiation [157].  In addition, the optimal carrier should help to define the shape of 
resulting new bone and should have a degradation rate that does not inhibit bone growth and 
prevent fibrous tissue formation or fibrous encapsulation of the carrier. There have been many 
studies demonstrating the osteopromotive effect achieved by the local application of the drug 
(table 2.2) with different carriers in various animal models [157]. 
 
Table 2.2 - Carriers and animal models used for the local application of simvastatin. 
Type of carrier Animal model Defect Reference 
Methylcellulose gel Miniature pigs Alveolar defects [146] 
Polylactic acid/ 
polyglycolic acid 
Wistar rats 
Extraction sockets in mandibular 
incisors 
[154] 
Gelatin Wistar rats Bone defect in mandible [155] 
Methylcellulose gel Beagle dogs Periodontal defects [158] 
Calcium sulphate Rabbits Ulnar defects [159] 
α-TCP Wistar rats Calvarial defects [160] 
 
Pradeep et al. has carried out  randomized clinical trials demonstrating that locally- adminis-
tered simvastatin, versus placebo, significantly improves the clinical outcomes of scaling and 
root planning for treating mandibular buccal Class II furcation defects [161] and in patients 
with chronic periodontitis [162]. 
Studies focusing on pharmacological development have tested several biodegradable polymeric 
formulas for the local delivery of simvastatin such as a hydrogel of gelatin [163] or microspheres 
of PLGA [164].  
The large majority of animal studies reported favorable results concerning topical application 
of simvastatin, either injected alone [165] or in combination with biomaterials [166], or cover-
ing acellular scaffolds [167]. Ozeç et al., make a 3 mm diameter defect in the angulus mandib-
ular region of Wista albino rats and grafted with simvastatin gelatin sponge producing 240% 
more new bone than the control group [155] . Nyan et al., create critical-sized bone defects in 
rat calvaria and treated with calcium sulfate or with combination of 1 mg simvastatin and 
calcium sulfate. It was reported that the combination of simvastatin and calcium sulfate stim-
ulated bone regeneration [156].  
Most animal studies performed intraorally have reported good results for topical simvastatin 
administration in enhancing bone regeneration in rat mandibular defects [168] and periodontal 
lesions in rats [144], [169], Beagles [158] and minipigs [146]. 
However, some authors have reported unfavourable results after using simvastatin for bone 
formation. Lima et al. [170] found a negative impact of combining simvastatin with demineral-
ized bovine bone matrix for repairing calvarial defects in rats after 30 to 60 days of healing.  
On postoperative day 60 the use of simvastatin, regardless of the dose, resulted in lower density 
than that observed in control and demineralized bovine bone matrix group samples.  
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Anbinder et al. also found that simvastatin administration, either orally or subcutaneously, did 
not improve bone repair for experimental tibial defects in rats [171].  
Regarding the dosing of the simvastatin, caution should be exercised. Some authors have re-
ported a dose-dependent inflammatory response [166].  In animal studies, a 0.1-0.5 mg dose of 
simvastatin would be the optimal dose for stimulating maximum bone regeneration without 
inducing inflammation [146].  
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Chapter 3 
Materials and methods  
 
 
 
Materials  
All reagents used were of laboratory grade and purchased from Sigma-Aldrich, unless stated 
otherwise. Dextrin - Tackidex was from Roquette. Dextrin-VMA was synthesized by transester-
ification of dextrin with vinyl methacrylate (VMA), with few modifications from the protocol 
described by Ferreira et al. [172] for the transesterification of dextran with VA. In this work, 
dextrin-VMA with 20 acrylate groups per 100 dextrin glucopyranoside residues was used. Re-
generated cellulose tubular membranes, were obtained from Membrane Filtration Products. All 
other chemicals and solvents used in this work were of the highest purity commercially availa-
ble. 
 
 
3.1 Glass reinforced hydroxyapatite (Bonelike) preparation 
In the present study, Bonelike granules size ranging from 250 to 500 µm were prepared as 
follows. First, a P2O5-based glass with the composition of 65P2O5-15CaO-10CaF2-10Na2O, in %mol, 
was prepared from reagent grade chemicals using platinum crucible at 1400ºC. The glass was 
ground and then the particles were sieved to a particle size less than 50 μm, using riddles with 
descending diameter. Medical grade hydroxyapatite was synthesized by chemical precipitation. 
After drying during 72 hours at 60ºC the hydroxyapatite was sieved until a particle size less than 
75 μm was obtained. Then, the hydroxyapatite was mixed with the glass in a proportion of 
2.5wt% [77], [81]. The mixed powders were dried for 24 hours at 60ºC and then sintered at 
1300ºC for 1 hour. Finally, using, using standard crushing and sieving techniques the desirable 
particle range (250-500 µm) was obtained. The obtained hydroxyapatite was submitted to X-
ray fluorescence spectrometry and X-ray diffraction (PANalytical, X'PERT-PRO model). Bonelike 
phase identification and quantification was performed using X-ray diffraction and Rietveld anal-
ysis.  
 
 
3.2 Preparation of oDex Hydrogel 
Dextrin Oxidation: 
Briefly, aqueous solutions of dextrin (2% w/v) were oxidized with a 2 mL sodium m-periodate 
solution, to yield the theoretical degree of oxidation of 40%, at room temperature, with stirring, 
and in the dark. After 20 h, the oxidation reaction was stopped by adding dropwise an equimolar 
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amount of diethyleneglycol to reduce any unreacted periodate. The resulting solution was dia-
lyzed for 3 days against water using a dialysis membrane with a molecular weight cutoff of 1000 
Da and then lyophilized for 10 days. The degree of oxidation (DO) of oxidized dextrin (oDex) is 
defined as the number of oxidized residues per 100 glucose residues and was quantified using 
the tert-butylcarbazate method [105].  
 
Preparation of oDex-ADH Hydrogels: 
oDex was dissolved in PBS buffer (phosphate-buffered saline) (30% w/v) at room temperature, 
and an adipic acid dihydrazide (ADH) solution (prepared separately) was added at the concen-
tration of 3,76% w/v. The cross-linking reaction was allowed to proceed during 30 minutes. The 
material was considered as gelified when it stopped slipping along a 90° inclined surface. The 
hydrogel preparation followed the protocol proposed by Molinos et al. [105]. 
 
 
3.3 Preparation of self-assembled nanoparticles of dextrin substituted with hexade-
canethiol 
For the nanoparticles preparation, the protocol proposed by Gonçalves et al. [131] was followed, 
as described ahead:  
 
Synthesis of dexC16: 
Dextrin-VMA and 1-hexadecanethiol were dissolved in dimethyl sulfoxide (equivalent VMA = 
0.0413 M). A molar percentage of 1-hexadecanethiol (100% relative to VMA) were added to the 
reaction mixture in order to obtain the pretended degree of substitution (DS). Triethylamine 
(TEA) (1 mol equiv to VMA) was added to the reaction mixture. The medium was stirred for 24 
h, at 50 ºC. The mixture was dialysed for 48 h against water with frequent water change. After 
freezing, the mixture was lyophilized and stored. 
 
Sample preparation: 
Lyophilized dexC16 was dissolved in water or PBS under stirring at 50 ºC until a clear solution 
was obtained. The degree of solubility of dexC16 depends on the degree of substitution. In-
creasing the degree of substitution reduces the solubility. In the range of DSC16 used, to pre-
pare a 1.0 g/dL solution, 3 h of stirring is the maximum time required to dissolve dexC16. 
 
Dynamic light scattering: 
The size distribution was determined with a Malvern Zetasizer, Model Nano ZS (Malvern Instru-
ments Limited, U.K.). A dispersion of nanoparticles in water (1 mL) was analysed at 25 ºC in a 
polystyrene cell using a Helium-Neon laser – wavelength of 633 nm and a detector angle of 173º. 
The dispersion was filtered through a 0.22 μm pore. 
 
1H NMR: 
Lyophilized dexC16 was dispersed in deuterium oxide (1.0 g/dL). Solutions were transferred to 
5 mm NMR tubes. 1D 1H NMR measurements were performed with a Varian Unity Plus 300 spec-
trometer operating at 299.94 MHz. 1D 1H NMR spectra were measured at 298 K with 80 scans, 
a spectral width of 4800 Hz, a relaxation delay of 1 s between scans, and an acquisition time 
of 3.75 s. 
3.4 Preparation of the oDex-Nanogel Hydrogels and Bonelike-oDex-Nanogel Hydrogels 
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oDex, DO 40%, (30% w/v) was dissolved in PBS or in a suspension of nanogel for ∼16 h at room 
temperature. Then, the oDex suspensions were mixed with 5% (in molar base taking into ac-
count the number of glucose residues in the original dextrin) ADH. The cross-linking was allowed 
to proceed at room temperature for 30 minutes. Ahead, the oxidized dextrin hydrogels are 
termed as oDex hydrogels, and the oxidized dextrin hydrogels with incorporated dextrin nano-
gels are called oDex-nanogel hydrogels. 
For the Bonelike-oDex-Nanogel Hydrogel, the same protocol was followed, but before adding 
the ADH, Bonelike (60% or 40% w/v) was added to the samples and stirred. Then, ADH was 
added to each sample and the cross-linking was allowed to proceed at room temperature for 
30 minutes.  
 
 
3.5 Cryo-Scanning Electron Microscopy (Cryo-SEM) Analysis 
The topography and porosity of the injectable bone graft substitutes (30% w/v oDex, 10 mg/mL 
nanogel and 40 or 60% w/v Bonelike) were studied by Cryo-SEM.  
The SEM / EDS analysis was performed using a High Resolution Scanning Electron Microscope 
with X-Ray Microanalysis and CryoSEM experimental facilities: JEOL JSM 6301F/ Oxford INCA 
Energy 350/ Gatan Alto 2500. The samples (n=3) were rapidly cooled (plunging it into sub-
cooled nitrogen – slush nitrogen) and transferred under vacuum to the cold stage of the prepa-
ration chamber. The specimens were fractured, sublimated (‘etched’) for 90 seconds at -90°C, 
and coated with Au/Pd by sputtering for 45 seconds and then transferred into the SEM chamber 
where were studied at a temperature of -150°C. 
 
 
3.6 Injectability tests  
The injectability tests were conducted at the Faculty of Pharmacy, University of Porto. The 
equipment TA.XT2i Texture Analyser was used to evaluate the extrusion force of injectables, 
in order to determine if they can be applied in a clinical environment. The tests were performed 
in triplicate per each testing condition. 1mL samples of the Injectable Bonelike-oDex-Nanogel 
Hydrogel were placed inside 2mL syringes, followed by a 30 minutes period to allow the cross-
linking reaction. The syringes were fixed vertically to the bottom plate and the equipment 
applied the necessary force to move the plunger 1 mm/s in the syringe. The results were ex-
pressed as the force required to move the plunger out of the syringe.  
 
 
3.7 Preparation of simvastatin-loaded Bonelike scaffolds and in vitro assay of simvas-
tatin release 
Simvastatin was dissolved in pure ethanol at a concentration of 5mg/mL. For the preparation 
of simvastatin-loaded Bonelike scaffolds, 100µl of the previous solution was dropped onto Bone-
like under sterile conditions, and then allowed to dry completely in a laminar flow hood for 24 
h. 2 groups of samples were prepared (n=3), containing 60 mg of Bonelike and 0 mg or 0.5mg 
simvastatin, respectively. 
The scaffolds (60 mg) were placed in 1 ml PBS at 37˚C at 60 rpm. At 24, 48, 72, 96, 168, 192, 
216 and 240 hours, the PBS was changed. At every time-point the solution absorbance was 
measured at a wavelength of 238 nm using an ultraviolet-visible spectrophotometer, while the 
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simvastatin concentration was determined from a standard curve prepared with various 
amounts of simvastatin.   
 
3.8 Incorporation of simvastatin in the nanogel  
Simvastatin (SIM) was loaded into the hydrophobic domains of nanoparticles. The physical en-
trapment of simvastatin in the nanoparticles was performed following the nanoparticles for-
mation, as described ahead. 2 stock solutions of simvastatin in ethanol with a concentration of 
5 mg/mL and 10 mg/mL were prepared. The required volume of simvastatin from these solu-
tions was added to the nanoparticles solutions (final concentration of ethanol < 1%). The effect 
of polymer/simvastatin ratio on the loading efficiency and stability of the formulation was 
studied. Different formulations were prepared by varying the concentrations of simvastatin (5 
mg/mL and 10 mg/mL) and polymer (1.0 and 3.0 mg/mL). In order to evaluate the entrapment 
efficiency, the solutions were kept under stirring during predeterminated times (3 and 24 hours). 
The resultant solutions were centrifuged at 10000 rpm, for 5 min, to remove the insoluble 
simvastatin. The supernatants were carefully collected and analyzed spectrophotometrically. 
The quantification was carried out using a calibration plot obtained with different simvastatin 
concentrations. The entrapment efficiency was calculated by the Equation 3.1:  
 
𝐸𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%) =  
[𝑆𝑖𝑚𝑣𝑎𝑠𝑡𝑎𝑡𝑖𝑛] 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑
[𝑆𝑖𝑚𝑣𝑎𝑠𝑡𝑎𝑡𝑖𝑛] 𝑎𝑑𝑑𝑒𝑑
× 100 ,    (equation 3.1) 
 
The size distribution of unloaded and loaded dextrin nanoparticles was determined by dynamic 
light scattering (DLS) using a Malvern Zetasizer, Model Nano ZS. The nanoparticles dispersion 
was analysed at 25ºC in a polystyrene cell, using a He-Ne laser - wavelength of 633 nm and a 
detector angle of 173º. The DLS analysis provides the characterization of a sample through the 
mean value (z-avg) for the diameter, and a width parameter known as the polydispersity index 
(PdI). 
 
 
3.9 In vitro assay of simvastatin release from the nanogel 
The release of simvastatin from the nanoparticles was studied using sink conditions. The simvas-
tatin loaded nanoparticles (5mg/mL of simvastatin and 1.0 mg/mL of polymer in an aqueous 
solution) was placed in a dialysis membrane.  
The dialysis membrane (molecular cut off of 2 kDa) was placed in 200 mL of PBS, shaken under 
250 rpm at 37ºC. At predefined timeframe (up to 24 h), a sample of 200 µL was withdrawn, 
centrifuged to guarantee removal of unentrapped simvastatin and the supernatant was ana-
lyzed spectrophotometrically.  
 
 
3.10 Materials sterilization  
Sterilization of Bonelike granules was performed by autoclaving the material during 35 minutes, 
at 121ºC. oDex hydrogel was sterilized by UV light, during 1 or 2 hours. To acess the efficacy of 
this method, sterilized samples (n=3) were immersed in αMEM during 4 weeks. The dextrin 
nanoparticles were sterilized by filtrating the dispersion through a 0.22µm pore (Sterile Cellu-
lose Acetate Membrane, Frilabo).  
 
3.11 MTT assay 
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Mouse embryo fibroblasts 3T3 (ATCC CCL-164) were grown in Dulbecco’s modified Eagle’s media 
supplemented with 10% newborn calf serum (Invitrogen, U.K.) and 1 μg/mL penicillin/streptav-
idin (cDMEM) at 37 °C in a 95% humidified air containing 5% CO2. Before reach confluency, 3T3 
fibroblasts were harvested with 0.05% (w/v) trypsin-EDTA and subcultivated in the same me-
dium. 
The cytotoxicity of the nanoparticles unloaded and loaded with simvastatin was assessed in a 
3T3 fibroblasts culture previously incubated for 24 h (2.0 × 104 cells/well, in a 24-well polysty-
rene plate, n=3) using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) as-
say, as described ahed. The nanoparticles were sterilized and dissolved in cDMEM. Increasing 
concentrations of loaded and unloaded nanoparticles (0.5, 0.75, 1 and 2 mg/mL) dissolved in 
cDMEM at 20% (v/v), were then added to the fibroblast culture. Free simvastatin, in the same 
concentration that was incorporated in the nanoparticles, was dissolved in cDMEM at 1% (v/v).   
After 24h and 48 h of incubation, cell viability was accessed by MTT assay. Morphological eval-
uation of 3T3 cells was also made by regular light microscope observations. 
 
 
3.12 In vivo tests 
The objective was to observe ectopic bone formation in subcutaneous implants in rats, due to 
simvastatin action, during an 8-week experiment. The injectable composite materials were 
sterilized by the methods previously referred.  
100 µl of samples were surgically implanted subcutaneously in the lumbar region of three male 
rats (Sasco Sprague Dawley, Barcelona, Spain, weighting around 300 g), each one receiving 5 
implants with the following scheme:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Previous experimental work already evaluated the biological response of rats using a control 
with no implant where the suture was performed (Sham group). Two animals were housed per 
cage (Makrolon type 4, Tecniplast, VA, Italy), in a temperature and humidity controlled room 
with 12-12h light/dark cycles, and were allowed normal cage activities under standard labora-
tory conditions. The animals were fed with standard chow and water ad libitum. Adequate 
Figure 3.1 - Implant scheme: (1) oDex-nanogel/SIMV hydrogel; (2) oDex-nanogel/SIMV hydrogel + MSCs; 
(3) oDex-nanogel hydrogel; (4) oDex-nanogel hydrogel + MSCs; (5) Bonelike/SIMV-oDex hydrogel; 
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measures were taken to minimize pain and discomfort taking into account human endpoints for 
animal suffering and distress. 
All procedures were performed with the approval of the Veterinarian Authorities of Portugal, 
and in accordance with the European Communities Council Directive of November 24th 1986 
(86/609/EEC). Anaesthesia was achieved with an intraperitoneal injection of a pre-mixed solu-
tion consisting in ketamine (Imalgene 1000R), 100 mg/kg body weight, and xylazyne (RompunR), 
200 mg/kg body weight. Hair from the dorsal area was clipped and the skin scrubbed in a routine 
fashion with an iodopovodone 10% solution (BetadineR). Five 1.5-2cm long linear incisions were 
performed. After blunt dissection towards the ventral aspect of the body, the biomaterials 
were implanted subcutaneously. Skin and subcutaneous tissues were closed with a simple-in-
terrupted suture of a non-absorbable filament (SynthofilR, Ethicon).  
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Chapter 4  
Results and Discussion  
 
 
 
4.1 Glass reinforced hydroxyapatite (Bonelike) preparation 
The obtained hydroxyapatite was submitted to X-ray fluorescence spectrometry to perform a 
chemical and elemental analysis. X-ray diffraction was used to identify and quantify the differ-
ent crystalline phases. The values of the tables 4.1 and 4.2 are inside the range of values of 
the norm ISO/DIS 13779-1 (Implants for surgery — Hydroxyapatite; Part 3: Chemical analysis 
and characterization of crystallinity and phase purity) [173].  
 
Table 4.1 - Quantitative chemical analysis of the hydroxyapatite1. 
Analytical parameter Obtained value Uncertainty Units 
Arsenic (As) <1.0
 q.l. *1 n.a. *2 mg/Kg 
Cadmium (Cd) <0.5 q.l. *1 n.a. *2 mg/Kg 
Mercury (Hg) <0.5 q.l. *1 n.a. *2 mg/Kg 
Lead (Pb)  <0.5 q.l. *1 n.a. *2 mg/Kg 
Ca/P  1.68 n.a. *2 Molar ratio 
 
Table 4.2 - Quantification of crystalline phases by X-ray diffraction of the hydroxyapatite. 
Crystalline phases Chemical formula wt% Uncertainty 
hydroxyapatite Ca10(PO4)6(OH)2 99 ±2 
α tricalcium phosphate Ca3(PO4)2 <1
q.l. *1 n.a. *2 
β tricalcium phosphate Ca3(PO4)2 <2
 q.l *1 n.a. *2 
calcium oxide CaO <1q.l. *1 n.a. *2 
tetracalcium phosphate Ca4(PO4)2O <2
 q.l. *1 n.a. *2 
                                                 
*1 q.l. quantification limit; *2 not applicable; 
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As table 4.1 shows, the molar ratio was the expected for hydroxyapatite and very similar to the 
human bone Ca/P molar ratio (1.631) [174]. 
During the sintering process of Bonelike, the CaO–P2O5 glass (also produced for this work) reacts 
with hydroxyapatite, forming β-tricalcium phosphate, which then can transform into α-trical-
cium phosphate at higher temperatures. Figure 4.1 display an X-ray diffraction pattern of Bone-
like [81]. Rietveld analysis previously reported indicated that Bonelike is composed by 68.4% of 
hydroxyapatite, 24% of α-TCP, and 7.6% of β-TCP [81], [175], [176].  
 
 
Figure 4.1 - X-ray diffraction pattern of Bonelike, which is composed of hydroxyapatite (HAp), α-TCP (α) 
and β-TCP (β) [81]. 
 
Bonelike has been reported to be osteoconductive and bioactive, supporting the formation of 
mechanically and chemically bonded bone directly on its surface [49], [51], [177]–[179]. A bal-
ance between the least soluble phase of hydroxyapatite and most soluble phase of tricalcium 
phosphate determines the bioactivity of Bonelike. Due to the presence of biodegradable α and 
β-TCP phases in the structure of Bonelike, a local enrichment in Ca and P in the physiological 
environment occurs, which stimulates new bone formation [175]. For this work, Bonelike with 
granules size ranging from 250 to 500 mm, as shown in figure 4.2, was obtained using using 
standard crushing and sieving techniques. A porosimetry of 65% for the Bonelike produced was 
reported previously, in our lab, using mercury intrusion porosimetry analysis.  
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Figure 4.2 - Glass reinforced hydroxyapatite (Bonelike) with a particle size from 250 to 500 µM; (A) 
macroscopic aspect of Bonelike granules and (B) SEM image showing the surface morphology. 
500  µm 
 
A 
B 
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The preparation of the Bonelike scaffold followed the standard protocol reported previously 
[77], [175]. 
 
 
4.2 Preparation of oDex Hydrogel 
Since the oDex hydrogel was already well studied and published [105], [107], [125], [130], the 
conditions that best fulfill the requirements for the final application of this work were chosen 
from the literature. Since the ultimate goal is the in vivo implantation, the cytotoxicity of the 
hydrogels was taken into account. The cytotoxicity of the oDex hydrogels, was evaluated and 
reported for the reticulating agent (ADH), oDex hydrogels, as well as its degradation products 
and the overall results point to the oDex hydrogels cytocompatibility [105].  
Through control of DO and ADH concentration, a good control over the gelation time was pos-
sible. A gelation time too long would make the injectable system inappropriate to use in clinical 
aplications, as it would unnecessarily prolong the time of medical protocols and consequently 
increase the cost of treatment. This would be impractical in clinical environment.  However, if 
the gelation time is too fast, it will prevent a good homogenization of the material, making 
difficult to obtain materials with reproducible characteristics. DO of 50% would originate gela-
tion periods inferiors to 1 minute and DO of 32,5% gelation periods of 30 minutes. In the range 
of values already tested [105], 40% was the chosen one, having gelation periods of around 2 
minutes.  
 
 
4.3 Preparation of self-assembled nanoparticles of dextrin substituted with hexade-
canethiol 
According to the protocol proposed by Gonçalves et al. [134], 1H NMR was used to analyse the 
structure of the reaction product. The signals between 5.8 and 3.0 ppm in the 1H NMR spectrum 
of dextrin are assigned to protons from the dextrin scaffold (Figure 4.3). As shown in this figure, 
the protons from the acrylate group, attached to the dextrin backbone are observed between 
1.9 and 2.1 ppm and 6.6 and 6.0 ppm [172]. 
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The reaction between the grafted acrylate and the thiol hexadecanethiol follows a mechanism 
of Michael addition [134] . The intensity of the signals from protons of the unsaturated carbons 
of the acrylate groups decreases as the reaction progresses, and the signals should eventually 
disappear completely when all acrylate groups are grafted with thiol moieties. Simultaneously, 
a new signal assigned to the methylene protons should appear.  
Although it was possible to identify the signals corresponding to the grafted alkyl moiety, be-
tween 2.0 and 0.6 ppm, the acrylate protons are still detected. Using TEA as a catalyst, the 
signals from thiol moieties have higher intensity and the acrylate signals completely disappear, 
confirming the success of the synthesis (Figure 4.4).  
 
Figure 4.3 - 1H NMR spectra of (A) dextrin and (B) dextrin-VMA (DSVMA 24%) in D2O at 25ºC. 
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Figure 4.4 - 1H NMR spectra in D2O of dextrin-VMA reacted with hexadecanethiol with TEA. 
 
The 1H NMR spectrum of dexC16, in deuterated water, was used to determine the degree of 
substitution obtained (DSC16, amount of alkyl chains per 100 dextrin glucopyranoside residues). 
DSC16 was calculated as a peak area ratio in the NMR spectra, according to Equation 4.1: 
 
𝐷𝑆 𝐶16 =  
7 ×𝑥
37 ×𝑦
 × 100 ,                             (Equation 4.1) 
 
where x is the average integral corresponding to the protons from alkyl moieties (2.0 - 0.6 ppm) 
and y is the integral of all dextrin protons (3.0 - 5.8 ppm). In this work, the DSVMA was 24% and 
DSC16 was 7%. Despite the nanoparticle size is only shlighty influenced by DSC16 [135], it has been 
already reported that with DSC16 7%, the mean diameter of nanoparticles ir roughly 20nm (de-
termined by DLS and AFM) [134]. The nanoparticles also remain stable up to two months, wich 
means that the particles kept their size and indicate the high colloidal stability of nanoparticles 
in the aqueous medium [135].  Small size, low density and high stability of the nanoparticles 
produced can promote a stable entrapment of bioactive and hydrophobic molecules, like 
simvastatin [135], [139].   
 
 
4.4 Preparation of the oDex-Nanogel Hydrogels and Bonelike-oDex-Nanogel Hydrogels 
The development of the injectable hybrid hydrogels consists in mixing glass reinforced hydrox-
yapatite (Bonelike) and oDex hydrogel to obtain a compact compound. Different combinations 
such as dextrin nanogel + oDex hydrogel and Bonelike + dextrin nanogel + oDex hydrogel were 
prepared for some tests. Two different ratios (40 and 60%) of hydrogel / Bonelike were studied.  
During the preparation of the samples for the Cryo-SEM analysis, a high concentration of dextrin 
nanoparticles was used to improve the chances of being observed during the analysis. It was 
observed macroscopically that the formulations with only oDex-nanogel hydrogel, with a nano-
gel concentration of 10mg/mL, result in improved mechanical properties (figure 4.5). The ma-
terial showed improved capacity to maintain a predetermined form and a greater cohesion 
dextrin 
thiol 
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when compared with Bonelike-oDex hydrogel (figure 4.6). According to the literature [105], 
[180]–[182], this can be attributed to a further reticulation of the hydrogel network.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For the injectability tests the same concentration of nanogel (10mg/mL) was used to deter-
mined if the extrusion force would be significally different. Although mass loss studies protocols 
Figure 4.6 - Bonelike oDex-nanogel hydrogel. 
Figure 4.5 - Macroscopic aspect of (A) Bonelike oDex-nanogel hydrogel, with 10mg/mL of dextrin 
nanoparticles and (B) Bonelike oDex hydrogel. 
B 
A 
B
2 cm 
1 cm 
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for this kind of materials show low fiability when the results are transposed to in vivo implan-
tation, it is already known that the degradation speed of oDex hydrogels is different from the 
oDex-nanogel hydrogels. It is expected that the oDex-nanogel hydrogel have a degradation 30% 
slower than the one observed in oDex hydrogels [105]. According to mass loss studies already 
published for oDex hydrogel, in approximately 25 days, the oDex hydrogel network is completely 
solubilized, whereas only ~70% mass loss was observed in oDex-nanogel hydrogels (nanogel con-
centration of 3mg/mL). However, these results correspond to a study where dextrin Koldex 60 
starch was used. For this work, a medical grade dextrin was used, Tackidex. Very recently, it 
was reported that the degradation time for oDex hydrogels made with dextrin Tackidex was of 
24 hours, in vitro [183]. The in vitro protocols involve mechanical manipulation of the hydrogels, 
inducing a faster degradation than the ones that occur in vivo.  
The relatively quick degradation rate of the Tackidex hydrogel is suitable for the purpose of 
this work where the hydrogel have to perform as an injectable carrier of Bonelike granules. 
Regarding the gelation time, it was noted that after adding the reticulating agent to the for-
mulation with Bonelike, nanogel and hydrogel (injectable Bonelike-oDex-nanogel hydrogel), the 
approximate gelation time for the DO of the hydrogel (40%) was a little higher than the one 
reported in the literature [105], [125]. It was reported gelation times of around 2 minutes, 
while during the preparation, with the conditions tested, gelation times between 8 and 15 
minutes were observed. This difference is due to the ceramic granules of Bonelike, which slow 
the gelation time. In fact, the optimal gelation time range suggested by surgeons has been 
defined between 5 and 30 minutes [184]. Therefore, for the purpose of this work, this increase 
in the gelation time will  allow that at the time of implantation, the surgeon can choose be-
tween a more viscous or more fluid material, that reticulate inside the syringe or in situ, re-
spectively. This represents very promising and suitable characteristics for the application of 
the injectable in clinical environment. 
 
 
4.5 Cryo-Scanning Electron Microscopy (Cryo-SEM) Analysis 
The dextrin nanogel and the Bonelike granules were incorporated in the oDex hydrogel, and 
the hybrid hydrogel was further characterized. Cryo-SEM analysis was used to examine the mor-
phologies of the injectables. As shown in figure 4.7 and described in literature [105], the cova-
lent cross-linking of the hydrogel produced tridimensional networks with a porous structure, 
with a diameter of ~1µm.  
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The Bonelike granules were completely and successfully incorporated in the hydrogel and re-
mained easily suspended in the hydrogel matrix (figure 4.8). Using larger amplifications, the 
nanogel particles can be observed in the matrix of the hydrogel (figure 4.9).  
 
Figure 4.7 - (A) Cross-section of oDex hydrogel and (B) detail of the porous structure. 
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Figure 4.8- Cryo-SEM  images from cross-section of (A) Bonelike granules completely embedded 
in the hydrogel matrix and (B) detail of the porous structure of the hydrogel inside Bonelike. 
A 
B 
Bonelike 
Bonelike 
hydrogel 
hydrogel 
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Figure 4.9 - Cryo-SEM images from (A) dextrin nanoparticles and (B) dextrin nanoparticles 
inside the oDex hydrogel matrix. 
A 
B 
hydrogel matrix 
nanogel 
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No morphological differences were noted comparing the oDex and oDex-nanogel hydrogel for-
mulations. As expected, the incorporation of the nanogels and the Bonelike granules did not 
have significant influence in the morphology of the oDex hydrogel network.  
The material produced is a three-dimensional, highly porous structure with interconnected po-
rosity, displaying characteristic that will serve as scaffold for tissue growth. 
  
 
4.6 Injectability tests  
During the injection of a formulation via a needle, the force applied to a syringe plunger is 
dissipated in three ways: (1) overcoming the resistance force of the syringe plunger; (2) im-
parting kinetic energy to the formulation; and (3) forcing the formulation through the needle 
[185]. The third topic should be adapted to the protocol that was performed in this work. The 
formulation was not extruded through a needle due to one main reason: having a formulation 
with ceramic granules does not allow the extrusion through the typical syringe with a needle 
of very small diameter, due to the size of the granules.   
In the tests performed, the top of the syringe was cutted, according preliminary tests. This was 
done not only due to the already referred reasons but also to allow comparing the results with 
other tests performed by our group, using different materials (data not shown). In figure 4.10, 
the results obtained for four diferent conditions are shown. As expected, the conditions with 
the Bonelike granules showed a higher extrusion force than using formulations just composed 
by oDex-nanogel.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) oDex hydrogel + dextrin nanoparticles (10mg/mL) + Bonelike (60% w/v) 
(B) oDex hydrogel + dextrin nanoparticles (10mg/mL) + Bonelike (40% w/v) 
(C) oDex hydrogel + dextrin nanoparticles (10mg/mL)  
(D) oDex hydrogel + dextrin nanoparticles (5mg/mL)  
 
D 
C 
A 
B 
Figure 4.10 - Extrusion profiles for the different injectables. 
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Table 4.3 - Injectability tests results. 
Injectable 
Maximum extrusion force 
[N] 
Average force of plateau  
area [N] 
A 29,15 20,93 (±5,15) 
B 26,39 20,15 (±7,36) 
C 10,64 8,87 (±0.40) 
D 5,46 5,22 (±0.73) 
 
In table 4.3 is shown the maximum extrusion force and the average of plateau area (±SD), 
obtained for the course between 2 and 10 mm. Statistical analysis using One Way Repeated 
Measures ANOVA, indicated that no statistical diference existed between A and B and between 
C and D. For the other combinations (A/C, B/C, A/D and B/D), existed significant statistical 
differences (p<0.05). The standard deviations for the conditions that contained Bonelike are 
relatively high when compared with the conditions where there was no Bonelike. This is due to 
different degrees of compaction of the material inside the syringe and small air bubbles that 
entered during the homogenization. The main purpose of this trial was to study the extrusion 
forces when using the maximum concentration possible of dextrin nanoparticles (10mg/mL) in 
the Bonelike and oDex hydrogel. Due to the nature of the assay, which requires large amounts 
of material, only the four conditions were analysed; in this way, we would get the maximum 
value of extrusion for the future formulations with nanoparticles. 
When these results are compared with other test performed in our lab, some conclusions arise. 
Preliminary assays, showed that oDex hydrogel have an average extrusion force of 3,91 N 
((±0.66). Adding dextrin nanoparticles to the formulation, increased the extrusion force for 
5,22 N (±0.73) and 8,87 N (±0.40), at 5mg/mL and 10mg/mL, respectively. This was already 
expected due to macroscopic observation. According literature, this is assigned to a further 
reticulation of the hydrogel network [105], [180]–[182].  
As expected, the conditions incorporating Bonelike in the hydrogels presented higher extrusion 
forces, due to the ceramic granules. Preliminary data, showed that the combination of oDex 
hydrogel + Bonelike (60% w/v) and oDex hydrogel + Bonelike (40% w/v) have an average force, 
in the plateau area, of 6,09 N (±0.51) and 4.74 N (±0.34), respectively. This demonstrates that 
the nanogel, at very high concentrations, significantly increases the composite extrusion forces. 
Khairoun et al. [186], [187] measured the injectability of a calcium phosphate bone cements 
and the force required to extrude reach values larger than 100 N, and hence was declared non-
injectable [188]. In this work, the results suggest that the formulations easily allow a surgeon 
to perform a smoothly extrusion of the material through a syringe thereby ensuring the inject-
ability of the hybrid material produced.  
 
 
4.7 Preparation of simvastatin-loaded Bonelike scaffolds and in vitro assay of simvas-
tatin release 
Very recent studies have successfully incorporated simvastatin in hydroxyapatite fiber [147] 
and calcium sulphate scaffolds [159], and reported that combinations of this scaffolds and 
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simvastatin stimulated new bone formation in a dose-dependent manner. Previous studies have 
investigated the effects of the local application of simvastatin. Stein et al. [189] reported that 
0.5 mg simvastatin appeared to be the optimal dose for single local application and this dose 
produced the best bone growth/inflammation ratio. In a study by Wong et al. [190], an aqueous 
solution with  0.5 mg of simvastatin was added to a collagen matrix in calvarial defects in 
rabbits and a 308% increase in new bone was present in the simvastatin-collagen group com-
pared with the collagen group alone at the end of 14 days. Based on these findings, this line of 
investigation was followed: simvastatin was used as growth-factor-like substance and Bonelike 
as scaffold. Based in previous reports [147], [159], [189], [190], 0.5 mg simvastatin was selected 
and incorporated into the Bonelike scaffolds for the in vitro release assays.  
The in vitro release pattern of simvastatin from the simvastatin-loaded Bonelike is shown in 
figure 4.15. In the first 24 hours, ~5.5% of simvastatin was release from the scaffold; this per-
centage of drug correspond to the solubility limit of simvastatin in the medium used. 
 
 
Figure 4.11 – Cumulative in vitro release of simvastatin from Bonelike. 
 
The release pattern observed in the following days, showed that simvastatin is released gradu-
ally over time, after an initial burst from Bonelike, which goes in accordance to the published 
literature with similar materials [147]. It is important to mention that the scaffold, drug and 
medium quantities used in this test were the same as reported in literature [147], [159] and 
the results are in accordance. This lead us to assume that initially, the simvastatin that were 
present at the surface of Bonelike dissolves easily in the PBS until reaches the drug solubility 
limit. However, with the passage of time, the simvastatin that was present in the Bonelike 
surface was dissolved totally and only simvastatin entrapped inside Bonelike pores remained, 
what could explain the slow release. Therefore, Bonelike is capable of promoting a slow but 
constant release of simvastatin due to characteristics inherent to the material. 
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4.8 Incorporation of simvastatin in the nanogel  
The possibility of enhancing simvastatin's solubility using dextrin nanoparticles as nanocarrier 
was investigated in this work. Therapeutic agents can either be physically entrapped into the 
polymeric matrix or covalently bound to the polymer backbone, being the physical drug entrap-
ment the more often used loading method for drug delivery applications [131], and the one 
that was used in this work. Physical drug loading can be performed by incorporating the drug 
while producing the nanoparticles, or by incubating a concentrated drug solution with the al-
ready formed nanocarrier.   
In this study, simvastatin was dissolved in a suitable solvent (ethanol) and exhibits absorption 
in the wavelength range from 200 to 255 nm, with a maximum absorption at 238 nm.  
Gonçalves et al [138]. have successfully loaded dextrin nanoparticles with curcumin, a lipo-
philic molecule and have reported that the addition of curcumin dissolved in ethanol to water 
(to a final concentration of ethanol < 1%), leads to curcumin precipitation. The addition of 
curcumin to aqueous solutions of nanoparticles results in a bright yellow solution, what suggest 
the entrapment of curcumin, presumably into the hydrophobic domains within the nanoparti-
cles [131]. While curcumin entrapment in the nanoparticles can be easily identified by the 
solutions with yellow colour, the simvastatin solutions are colorless. The dextrin nanoparticles 
in water originate a colloidal stable solution over 2 months; if the nanoparticles are centrifuged 
(<16000 rpm), they will not precipitate. Having this in mind, preliminary tests had place to 
determine if it was possible to load simvastatin in the nanoparticles. To aqueous nanoparticles 
solutions with diferent concentrations was added simvastatin dissolved in ethanol (to a final 
concentration of ethanol < 1%), centrifuged at 10000 rpm during 5 minutes. With nanoparticles 
solutions only a small white precipitate was formed at the bottom of the eppendorfs, while 
with the water control solutions all the simvastatin precipitated. This suggested the entrapment 
of simvastatin in the nanoparticles that was confirmed by UV spectra that reveal the same 
profile as the simvastatin dissolved in ethanol.  
To evaluate entrapment efficiency, different parameters were tested, in particular the simvas-
tatin and nanoparticles concentration and the encapsulation time. The results are presented in 
figure 4.13: 
Figure 4.12 - Simvastatin loading into dextrin nanoparticles of different formulations varying the 
simvastatin (5 or 10 mg/mL), the nanoparticles (1 or 3 mg/mL) and time (3 or 24 hours). 
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As expected, there is an optimal proportion between drug and polymer that allows a better 
entrapment efficacy, which in this case was registered at 5 mg/mL of simvastatin and 3 mg/mL 
of dextrin nanoparticles, during 3 hours. Higher concentrations of simvastatin decrease the 
entrapment efficacy, as expected. At 3 hours, where the best results were found, 5mg/mL have 
efficacy of ~70-75%, while at 10mg/mL amounted to ~30-45%. Doubling the drug concentration 
reduce to half the entrapment efficacy. These findings indicate that 5mg/mL of simvastatin 
could be the maximum concentration limit for the incorporation of simvastatin in the dextrin 
nanoparticles. The nanoparticles are interesting drug delivery systems since they can control 
and sustain  drug release at the target site, improving the therapeutic efficacy and reducing 
side effects [131]. In this work, the drug loading is relatively high and was achieved without 
chemical reactions; this is an important factor for preserving the drug activity [131], [138].  
The polydispersity index (Pdl) is helpful in the characterization of the size distribution. Pdl-
values close to 1 are indicative of heterogeneity [134]. The mean diameters (z-avg) of unloaded 
and simvastatin-loaded nanoparticles were found to be 20 nm (Pdl 0.452) and 28 nm (Pdl 0,615) 
for PBS solution, respectively. These are fairly high Pdl values, suggestive of significant polidis-
persity. This increase in size is in accordance with the published literature [138]. 
 
 
4.9 In vitro assay of simvastatin release from the nanogel 
For the in vitro release of simvastatin from the dextrin nanoparticles, sink conditions were used. 
A drug release assay should use a sufficient volume of dissolution medium, which should be 
able to dissolve the expected amount of drug released from the sample. The ability of the 
medium to dissolve the expected amount of drug is known as a sink condition.  
In this work, the soluble drug was quantified spectrophotometrically after centrifugation. This 
methodology is based on the fact that unentrapped simvastatin precipitates after centrifuga-
tion, as referred before. Only the entrapped simvastatin (0,1mM) in the nanoparticles is being 
quantified, since the sample was removed from inside the dialysis membrane.  
A sustained release of simvastatin was observed (figure 4.14); After 1 and 3 hours, the fractions 
of simvastatin released to the PBS were respectively 26,1% and 43,7%.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13 - In vitro simvastatin release from dextrin nanoparticles (1mg/mL). 
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The release profile without initial burst indicates the absence of simvastatin adsorbed on the 
surface of nanoparticles [191].The low size of the dextrin nanoparticles may explain the com-
plete release of simvastatin in 24 hours, since drug release is affected by particle size. Drug 
associated with small particles would be at or near the nanoparticle surface, which leads to a 
faster drug release. Larger particles have larger cores, which allows more drug encapsulation 
per particle, providing a slower release [192].  Nevertheless, it is not expected that in an in 
vivo implant the release would occur in 24 hours. The in vivo injectable sample will have the 
nanoparticles inside the hydrogel matrix, which will prolong the release of simvastatin. Molinos 
et al. reported the release of the dextrin nanogel from the oDex-nanogel hydrogels. The nano-
gel was gradually release over time, paralleling the hydrogel degradation [105]. Therefore, it 
is expected that the release of simvastatin from the nanogel, follow the release of the nanogel 
from the hydrogel providing a steady and continuous release up to 1-2 weeks. 
 
 
4.10 Materials sterilization  
Being the injectable composed by different materials with very different properties, the steri-
lization procedures were made separately and then all materials were joined in aceptical and 
sterilized conditions. The sterilization process for the Bonelike and for the nanoparticles was 
already reported; the same methods were used in this work [49], [81], [131], [136].  
Regarding the oDex hydrogel, some concerns arose about the reported sterilization process 
used in previous tests, where the hydrogel was sterilized by ethylene oxide [105]. The material 
has to be sterilized after the lyophilization process and before adding the reticulating agent. 
During this period, the material have a cotton-like texture and when sterilized by ethylene 
oxide, the gas enters to the material and effectively sterilize the hydrogel. However, after this 
process, the material has to rest during ten days and, more important, the reticulation time of 
the hydrogel increases. This indicate that the sterilization process is affecting the hydrogel 
matrix. In order to overcome this situation, other possibilities were studied, namely gamma 
radiation and ultraviolet radiation, but due to costs and time issues, only ultraviolet radiation 
efficacy was evaluated in this work.  Samples of lyophilized hydrogel were immersed in αMEM 
to evaluate if the medium became cloudy or changed color due to bacterial growth. After four 
weeks, the medium remained with the same color and characteristics. More relevant, when UV 
sterilized samples of the hydrogel were reticulated, the gelation time was not altered, what 
allow to conclude that our material was successfully sterilized. 
 
 
4.11 MTT assay 
Simvastatin-loaded nanoparticles cytotoxicity was evaluated in vitro, using the 3-(4,5-dime-
thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The tetrazolium salt is widely 
used to quantify cytotoxicity, by colorimetry. The tetrazolium salts are metabolically reduced 
to highly coloured products, formazans. The colourless MTT is cleaved to formazan by the suc-
cinate-tetrazolium reductase system that belongs to the mitochondrial respiratory chain and is 
active only in viable cells [136].  
In this study, mouse embryo fibroblasts 3T3 cells were used. Figure 4.16 depicts the MTT ab-
sorbance values obtained after 24 and 48 hours of incubation. 
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High concentrations of nanoparticles were tested, comparing with previous reports [136], [138]; 
this was due to the results of the tests of simvastatin incorporation in the nanoparticles, were 
3 mg/mL registed the better results. However, to have a concentration of 3 mg/mL would be 
necessary to produce a sotck solution of nanoparticles at a concentration of 15 mg/mL, since 
the nanoparticles solutions were dissolved in cDMEM at 20% (v/v). This value was above the 
solubility limit of the material, so the highest concentration used in the cells was 2 mg/mL. 
In the first 24 hours, the presence of nanoparticles and simvastatin-loaded nanoparticles does 
not affect cell metabolic activity. The cells showed an optical density similar to the control 
(t24h, untreated cells). 
At 48 hours, the conditions with simvastatin loaded nanoparticles registered a low cell meta-
bolic activity. This occurs due the release of simvastatin from the nanoparticles that happens 
during the first 24 hours. However the effects are not immediate, as can be seen in the first 24 
hours of the condition with free simvastatin. Only at 48, the free simvastatin induced cell death. 
The nanoparticles at a concentration of 2mg/mL was not cytotoxic, but a cell proliferation 
inhibition can be observed at 48h. The simvastatin loaded nanoparticles (2mg/mL) induced cell 
death due to the joint action of the high nanoparticle concentration and simvastatin that was 
released for the medium. Although not statistically significant, existed biological differences 
in the conditions with simvastatin-loaded nanoparticles at 2mg/mL and free simvastatin where 
cell death at 48 hours occurred.  
While the free simvastatin induced cell death and inhibited cell proliferation, the simvastatin 
loaded nanoparticles (0.75 and 1) did not induced cell death, comparing with the timepoint t0. 
Figure 4.14 - Cells metabolic activity for different concentration of nanoparticles (0.75, 1 and 2 mg/mL), 
nanoparticles loaded with simvastatin and free simvastatin, assessed by MTT assay. Results presented as 
average ± SD (n=3). Statistical analysis were performed using a 2-way ANOVA. The comparison between 
diferent time points and t0 control are represented as n.s.1: non significant, p>0.05; *p<0.05; ***p<0.001. 
n.s.2: non significant, p>0.05; # p<0.05; ### p<0.001, represents each condition compared with the con-
trol (DMEM) at each timepoint (24 and 48 hours). 
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This showed the capacity of the nanogel to incorporated and produce a sustained release of 
the simvastatin, protecting the cells from the effects of the free simvastatin.  
The overall results showed that the nanoparticles, at the concentrations studied, do not in-
duced cell death. However, high concentrations of nanoparticles can constrain cell proliferation.  
In an in vivo application, it is expected that the results will be differents. While in the condi-
tions tested the high concentration of nanoparticles inhibit cell proliferation, in the final in-
jectable composite the nanoparticles will be within the hydrogel matrix, where they will have 
a slow release to the medium. In this case, the effects of high nanoparticles concentration and 
simvastatin will be attenuated.  
 
 
4.12 In vivo tests 
The in vivo tests are still in progress, so the results are not described in this work.  
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Chapter 5 
Conclusions and Perspectives  
 
 
 
The main purpose of the present work has been the development of an injectable bone substi-
tute compose by a modified calcium phosphate (Bonelike) suspended in a dextrin hydrogel car-
rier. The possibility of use the injectable composite as a simvastatin carrier was also evaluated 
with different lines of investigation, namely with the incorporation in the Bonelike and in dex-
trin nanoparticles. The results obtained lead to the following main conclusions:  
The composite system presented the capacity of being injected through a syringe and display 
gelation times suitable for the application in clinical environment.  
Cryo-SEM analysis revealed that Bonelike granules are fully dispersed in the hydrogel matrix; 
the material produced is a three-dimensional, highly porous structure with interconnected po-
rosity, displaying characteristic that will serve as scaffold for tissue growth.  
The straightforward incorporation of simvastatin in the Bonelike and the slow but constant 
release of simvastatin to the medium makes the Bonelike an interesting simvastatin carrier, 
with similar results to the published literature for similar materials.  
Taking advantage of nanotechnology in the drug delivery field, dextrin nanoparticles were used 
for improving simvastatin solubilisation and controlling its release profile. Despite the drug 
release occurs in a timeframe of 24 hours, it is expected that in the composite system this 
release is prolonged in time, up to 1-2 weeks.  
Sterilization methods for the hydrogel was also addressed, and a successful method (ultraviolet 
radiation) that does not alter the reticulation time of the oDex hydrogels was found.  
The evaluation of the cytotoxicity of the simvastatin loaded nanoparticles indicated the pro-
tective effect of the nanoparticles over the free simvastatin during 48 hours, and proved the 
effective release of simvastatin from the nanoparticles.  
The use of injectable systems in bone tissue engineering is still in its early stages; however, the 
proposed system may constitute an advanced delivery system for simvastatin and a promising 
injectable composite material for bone regeneration.  
 
The following goals are proposed for future work:  
 Optimizing in vitro testing methodology for recreate similar conditions to the in vivo 
applications to extract more information about the behaviour of the composite sys-
tem;  
 Study the interaction between the scaffold material, its architecture and therapeutic 
agents, with the cells to fully understand how to regenerate engineered bone. 
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 Explore the incorporation of other drugs and micro or nanoparticles in the composite  
system;  
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